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ComplementDengue virus (DENV) NS1 is a versatile non-structural glycoprotein that is secreted as a hexamer, binds to the
cell surface of infected and uninfected cells, and has immune evasive functions. DENV NS1 displays two
conserved N-linked glycans at N130 and N207. In this study, we examined the role of these two N-linked
glycans on NS1 secretion, stability, and function. Because some groups have reported reduced yields of
infectious DENV when N130 and N207 are changed, we analyzed glycosylation-deﬁcient NS1 phenotypes
using a transgenic expression system. We show that the N-linked glycan at position 130 is required for
stabilization of the secreted hexamer whereas the N-linked glycan at residue 207 facilitates secretion and
extracellular protein stability. Moreover, NS1 mutants lacking an N-linked glycan at N130 did not interact
efﬁciently with complement components C1s and C4. In summary, our results elucidate the contribution of N-
linked glycosylation to the function of DENV NS1.by hamster kidney ﬁbroblast;
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Dengue virus (DENV) is amosquito-transmitted Flavivirus of global
medical concern. Annually,more than 50 million human infections are
reported with approximately 25,000 deaths due primarily to dengue
hemorrhagic fever and shock syndrome (DHF/DSS) (Gubler, 1998;
Halstead, 2007). Four serotypes of DENV circulate and severe disease is
preferentially associated with secondary infection with a different
serotype. Although antibody-dependent enhancement of DENV
infection in Fc-γ receptor-bearing cells has been proposed to initiate
pathogenesis (Halstead, 1988), the precise pathologic mechanism
for DHF/DSS remains uncertain. Effects of virulent strains, a pro-inﬂammatory cytokine storm secondary to exuberant activation of
poorly lytic cross-reactive T cells, and excessive complement activa-
tion also have been proposed to cause the capillary leakage syndrome
associated with DHF/DSS (reviewed in Clyde et al., 2006).
The ~11 kb genomic RNA encodes a polyprotein that is cleaved by
viral and host proteases to generate three structural (capsid (C), pre-
membrane/membrane (prM/M) and envelope (E)) and seven non-
structural (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) proteins.
DENV NS1 is a 48 kDa non-structural glycoprotein that contains
twelve invariant cysteine residues, six intramolecular disulﬁde bonds,
and two conserved N-linked glycans (Chambers et al., 1990). Within
infected cells, NS1 expression is required for efﬁcient viral RNA
replication through an uncertain mechanism (Khromykh et al., 1999;
Lindenbach and Rice, 1997; Mackenzie et al., 1996). DENV NS1 is
translocated into the endoplasmic reticulum through a signal se-
quence localized near the C-terminus of E protein. Within the en-
doplasmic reticulum, DENV NS1 is modiﬁed such that N-linked
glycans are added at positions N130 and N207 (Falgout and Markoff,
1995). Further modiﬁcation occurs during transit through the Golgi
complex where a complex-type sugar is added to the N130 glycan but
the N207 glycan is retained in the high mannose form (Pryor and
Wright, 1994). NS1 is secreted at high levels into the extracellular
environment during DENV infection, predominantly as a hexamer
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in the sera of infected patients (Alcon et al., 2002; Avirutnan et al.,
2006; Libraty et al., 2002; Young et al., 2000). Soluble NS1 also can
bind back to the plasma membrane of cells through an interaction
with speciﬁc sulfated glycosaminoglycans (GAGs) (Avirutnan et al.,
2007). Finally, NS1 is expressed directly on the surface of infected
cells, possibly via glycosylphosphatidyl inositol (GPI) linkage (Jacobs
et al., 2000), lipid raft association (Noisakran et al., 2008) or through
an as yet undeﬁned mechanism.
NS1 has been implicated in DENV pathogenesis through mecha-
nisms that are enigmatic. High plasma levels of NS1 and terminal com-
plement complex C5b-9 detected in DENV-infected patients correlate
with severe disease outcome (Avirutnan et al., 2006; Libraty et al.,
2002). NS1 has been proposed to enhance infection in hepatocytes in
cell culture (Alcon-LePoder et al., 2005), facilitate immune complex
formation (Avirutnan et al., 2006), elicit auto-antibodies that cross-react
withplatelet and extracellularmatrix proteins, andpromote endothelial
cell damage via antibody-dependent complement-mediated cytolysis
(Chang et al., 2002; Lin et al., 2003; Sun et al., 2007). NS1 also has
immune evasion functions as it can directly antagonize complement
activation. West Nile virus (WNV) NS1 binding and recruitment of
factor H, a negative regulator of the alternative pathway, decreases
complement activation and C5b-9 membrane attack complex deposi-
tion on the cell surface (Chung et al., 2006a). DENV NS1 also exhibits
complement antagonistic activity by binding C4 and C1s, leading to C4
degradation and depressed complement activation (Avirutnan et al.,
2010). Finally, soluble DENV NS1 may interact with clusterin, a
complement regulator that inhibits terminal complement complex
formation (Kurosu et al., 2007). Attenuation of complement activation
by NS1 protects DENV from direct complement-dependent neutraliza-
tion by mannose binding lectins (Avirutnan et al., 2010; Fuchs et al.,
2010).
Several studies with different Flaviviruses have suggested that the
N-linked glycans on NS1 are essential for its function. A Yellow Fever
virus (YFV) NS1 mutant lacking the ﬁrst N-linked glycosylation site
(N130) exhibited a decrease in viral growth, reduced plaque size,
delayed cytopathic effect, and impaired NS1 secretion (Muylaert et al.,
1996). Mutation of the ﬁrst or both DENV NS1 N-linked glycosylation
sites also caused reduced virus growth (Crabtree et al., 2005; Pryor
et al., 1998; Tajima et al., 2008). In vivo experiments have shown that
loss of N-linked glycans on NS1 results in attenuated YFV, DENV, and
WNV infection in mice (Muylaert et al., 1996; Pryor et al., 1998;
Whiteman et al., 2010).
Because of the potentially confounding impact on viral replication,
we studied the effects of mutant forms of NS1 lacking either the ﬁrst
(N130), second (N207) or both N-linked glycans on the biology of NS1
in a heterologous viral system. We generated recombinant double
subgenomic Sindbis viruses (SINV) that ectopically express wild type
or mutant NS1 lacking either the ﬁrst (N130), second (N207) or both
N-linked glycosylation sites to compare the phenotypes of cell surface
expression and binding, secretion, stability, and interaction with
complement proteins. Mutation of N207 altered secretion and cell
surface levels of NS1. In comparison, mutation of N130 affected the
stability of hexameric NS1 and bound less well to human C4, C4b, C1s
proenzyme, or C1s. In summary, N-linked glycosylation on NS1 mod-
ulates cell surface expression, secretion, stability, and function.
Results
Generation of SINV encoding DENV-2 NS1
According to prior reports, DENVmutants lackingN-linked glycans
on NS1 are attenuated and fail to replicate efﬁciently in mammalian
cells (Crabtree et al., 2005; Pryor et al., 1998; Tajima et al., 2008). To
study the effects of N-linked glycosylation on NS1 in a system that is
not affected by changes in infectivity, we generated recombinantdouble subgenomic Sindbis viruses (SINV) that express ectopically
wild type or mutant NS1 lacking either the ﬁrst (N130), second
(N207) or both N-linked glycosylation sites (Fig. 1A). As expected,
recombinant SINV encoding wild type and mutant DENV-2 NS1
replicated equivalently (Fig. 1B), conﬁrming that expression of the
variant DENV-2 NS1 did not differentially affect SINV replication. This
was corroborated by analyzing levels of total and surface expression
of SINV envelope protein 2 (SINV E2) in infected cells by ﬂow
cytometry (Figs. 1C and D).
The second N-linked glycosylation site (N207) inﬂuences surface
expression and secretion of DENV NS1
Next, we determined the level of DENV-2 NS1 expression in
infected cells using the 1F11 anti-DENV-2 NS1MAb, which recognizes
a linear determinant on NS1 (Puttikhunt et al., 2003). Importantly,
consistent with the data of SINV E2 expression (Figs. 1C and D), the
total (intracellular+surface) levels of NS1 expression were compa-
rable in cells infected with SINV expressing wild type and all gly-
cosylation mutants of NS1 (Fig. 2A). However, N207Q and N130Q/
N207Q showed reduced surface expression of NS1 (2.6-fold, Pb0.05),
suggesting that the N-linked glycan at N207 is important for ac-
cumulation of DENV NS1 on the plasma membrane (Fig. 2B).
Flavivirus NS1 displayed on the surface of cells can arise from two
sources: a dimeric form that directly associates with the plasma
membrane (Winkler et al., 1989) through an unidentiﬁed mechanism
that requires charged amino acids near the NH2-terminus of NS1
(Youn et al., 2010), or a secreted hexamer that binds back to sulfated
GAGs on the cell surface (Avirutnan et al., 2007). To begin to address
how mutation of the N-linked glycan at the N207 position altered
surface levels, we assessed whether loss of N-linked glycans
modulated secretion of NS1. Supernatants from BHK21 cells infected
with wild type or glycosylation mutants of SINV-DENV-2-NS1 were
harvested at 18 h after infection and analyzed with an NS1 capture
ELISA. Notably, we observed no signiﬁcant difference in the levels of
NS1 secretion between wild type (5.00 μg/ml) and N130Q (4.43 μg/
ml) NS1 (PN0.5), whereas the levels of N207Q and N130Q/N207Q
were 10–25-fold reduced (0.46 μg/ml and 0.19 μg/ml, respectively;
Pb0.0001) (Fig. 2C). Thus, the N-linked glycan at position N207 is
crucial for accumulation of DENV NS1 in the supernatant.
To assess whether the difference in surface expression levels of
wild type and the N207Q mutant of NS1 was due to differential
binding back to the plasma membrane of soluble secreted NS1, we
treated BHK21 cells with 20 mM sodium chlorate at 6 h after SINV
infection to deplete the surface GAGs (Baeuerle and Huttner, 1986).
Treatment of the cells with sodium chlorate did not appreciably alter
total (intracellular+surface) NS1 expression (Fig. 2D). In compari-
son, reduction of surface sulfated GAGs resulted in similar surface
levels of NS1 regardless of whether cells were infected with SINV-
DENV-2-NS1 wild type or mutant proteins (Fig. 2E); interestingly,
with sodium chlorate treatment, the surface levels of wild type NS1
were equivalent to that seen with N207Q or N130Q/N207Q in
untreated conditions (Fig. 2B). These ﬁndings were not explained by
a marked reduction of NS1 in the supernatant as a consequence of
sodium chlorate treatment, as only a two- to three-fold decrease in
NS1 levels was detected in the supernatant of cells infected with SINV
expressing wild type and N130Q NS1, and both wild type and N130Q
still retained several-fold higher NS1 levels than the N207Q mutants
(Fig. 2C). Collectively, these data suggest that the increased cell
surface expression of wild type and N130Q NS1 is due to the higher
levels of secreted NS1 that accumulate and bind back to the plasma
membrane.
N-linked glycans have been shown to facilitate the interaction of a
glycoprotein with cellular chaperones to obtain its ﬁnal correct
conformation andprocessing through the secretorypathway (Trombetta
and Helenius, 1998). To determine whether the lower level of secretion
Fig. 1. Expression of wild type and N-linked glycan mutant DENV NS1 does not differentially affect SINV replication. (A) Schematic diagram of SINV vector encoding DENV NS1
constructs. Wild type or mutants with a glutamine substitution at the ﬁrst (N130Q), second (N207Q), or both glycosylation sites (N130Q/N207Q) of DENV-2 NS1 were inserted into
SINV 39HK vector backbone after the nonstructural nsP1–4 and structural proteins, capsid, envelope 1 and 2. The leader sequence was derived from the last 24 amino acids of DENV-
2 E protein. A hexa-histidine tag (His6 Tag) was added onto the carboxy-terminus of each construct. The boxes indicate glutamine for asparagine substitutions within the
glycosylation sites and arrows indicate the sites of mutations. CHO indicates the position of N-linked glycans. (B–D) Transgenic expression of variant DENV NS1 does not affect SINV
replication. BHK21 cells were infected with SINV expressing wild type and NS1mutants at anMOI of 1.0. The supernatants were collected 18 h post-infection and subjected to plaque
assay (B). Level of SINV infection was also assessed by total (C) and surface (D) SINV-E2 staining with mouse hyper-immune serum against SINV.
255P. Somnuke et al. / Virology 413 (2011) 253–264of N207Q and N130Q/N207Q was due to protein misfolding that could
impair transport through the cellular secretory pathway, we analyzed
total and cell-surface NS1 in SINV-DENV-2-NS1 infected cells using
conformation-dependent monoclonal (9NS1) (Figs. 2F and G) or
polyclonal antibodies (Figs. 2H and I), and compared this to 1F11,
which recognizes a linear determinant on NS1 (Figs. 2A and B). The
reactivity of these antibodies for wild type and mutant NS1 wasestablished after boiling in the presence or absence of β-mercaptoetha-
nol, with subsequent SDS-PAGE andWestern blot analysis (Fig. 2J); only
1F11 detected wild type and mutant NS1 under both non-reducing and
reducing conditions, as 9NS1 and polyclonal antibodies failed to
recognize any form of NS1 under reducing condition. Consistent with
the data observedwith 1F11 (Figs. 2A and B), N207Q and N130Q/N207Q
displayed lower levels of surfaceNS1expressioncompared to thatofwild
Fig. 2. N-linked glycan (N207) is important for surface localization and secretion of DENV NS1. (A–E) Decreased surface localization and secretion were observed in N207Q and
N130Q/N207Q mutant NS1. Infected cells were harvested at 18 h post-infection and total (A) and surface (B) DENV NS1 expression was determined by immunoﬂuorescence using
1F11 anti-DENV-2 NS1 MAb, which recognizes a linear epitope on NS1. Levels of secreted NS1 were quantiﬁed by ELISA of supernatants harvested at 18 h post-infection (C, open
bars). To deplete cellular pools of sulfated GAGs, cells were treated with 20 mM sodium chlorate at 6 h after infection and the cells and supernatants were harvested 12 h later for
analysis of total (D) and surface NS1 (E) by immunoﬂuorescence using NS1-speciﬁc MAb 1F11 and secreted NS1 levels by ELISA (C, ﬁlled bars) respectively. (F–I) Conformation-
dependent anti-NS1 antibodies did not efﬁciently recognize N207 mutants. Infected cells were harvested at 18 h post-infection and total (F and H) and surface (G and I) DENV NS1
expression was determined using the conformational-dependent cross-reactive 9NS1 MAb (F and G) and polyclonal anti-DENV-2 NS1 (H and I). J. Immunoreactivity of puriﬁed wild
type and NS1 mutants. Equal amounts (100 ng) of wild type and mutant NS1 were boiled prior to 4–12% SDS-PAGE in the presence (reducing) or absence (non-reducing) of β-
mercaptoethanol. Western blot analysis was performed subsequently with 1F11, 9NS1 or polyclonal anti-NS1. Error bars indicate standard error of the mean (SEM) from ﬁve
independent experiments. Asterisks indicate statistical signiﬁcance of NS1 secretion compared to wild type DENV2 NS1 (n.s., not signiﬁcant; *, Pb0.05; ***, Pb0.0001). Histograms
represent 3 to 5 independent experiments.
256 P. Somnuke et al. / Virology 413 (2011) 253–264type andN130Q (Figs. 2G and I). However, in contrast to the results with
1F11, the total (intracellular+surface) levels of N207Q and N130Q/
N207Qdetected by both conformation-dependent NS1 speciﬁc Abswere
decreased (Figs. 2F andH). These results suggest that the conformationof
N207Q and N130Q/N207Q is different, and potentially misfolded, from
that of wild type and N130Q NS1.
N-linked glycosylation does not affect NS1 binding to the cell surface
Soluble DENV-2 NS1 binds directly to different types of cells
including epithelial and mesenchymal cells in a GAG-dependent
manner (Avirutnan et al., 2007). As alteration of N-linked glycosyl-
ation on proteins can interfere with GAG interactions (Hershkovitz
et al., 2008), we assessed the binding efﬁciency to the cell membraneof NS1 lacking N-linked glycans. We puriﬁed the NS1 variants from
supernatants of SINV-DENV-2-NS1 infected BHK21 cells by immu-
noafﬁnity chromatography. We obtained relatively large amounts of
puriﬁed wild type and N130Q NS1 from small starting volumes.
However, because of the low yield for N207Q and N130Q/N207Q,
larger volumes were required. Western blot of wild type NS1
demonstrated bands that corresponded to those obtained with silver
staining (Figs. 3A and B), and were primarily in a monomeric form (as
expected), after boiling and solubilization in SDS. N130Q (Figs. 3C and
D), N207Q (Figs. 3E and F) and N130Q/N207Q (Figs. 3G and H) all
migrated at lower molecular weights secondary to their loss of N-
linked glycan(s). Consistent with previous ﬁndings under these
solubilization conditions, NS1 also migrated as a dimer in all samples.
This conﬁrms that glycosylation did not affect NS1 dimerization
Fig. 3. N-linked glycosylation does not affect secreted DENV NS1 from binding back to the cell surface. Wild type and mutant NS1 were puriﬁed by immunoafﬁnity chromatography.
Serum-free supernatants from SINV-DENV-2-NS1 infected BHK21 cells at an MOI of 1.0 were collected at 18 to 20 h post-infection and puriﬁed over an anti-NS1 MAb 2G6 column.
Samples of eluted fractions were boiled prior to 4–12% SDS-PAGE under non-reducing conditions and analyzed by Western blot with 1F11 anti-DENV-2 NS1 MAb (wild type (A),
N130Q (C), N207Q (E) and N130Q/N207Q (G)) and silver staining (wild type (B), N130Q (D), N207Q (F) and N130Q/N207Q (H)); the numbers below each gel correspond to the
eluted fractions. (I–K) Binding of wild type and mutant NS1 to the cell surface depends on GAGs. Immunoafﬁnity puriﬁed NS1 (10 μg/ml) (I) or serum-free supernatants of SINV-
DENV-2-NS1-infected cells containing 2 μg/ml of NS1 (J) were incubated with BHK21 cells and NS1 binding was detected by 2G6 anti-DENV-2 NS1MAb. Binding was also performed
after BHK21 cells were pre-treated with 20 mM sodium chlorate overnight and incubated with puriﬁed NS1 (K). Histograms are representative of 3 independent experiments.
257P. Somnuke et al. / Virology 413 (2011) 253–264(Pryor et al., 1998; Pryor and Wright, 1994), although we did observe
degradation products in the N207Q NS1 variants (Figs. 3F and H).
Notably, NS1without N130 glycosylation (N130Q and N130Q/N207Q)
appeared as a sharper band when compared to that of wild type or
N207Q NS1, which still had intact complex oligosaccharides at N130
(Figs. 3D and H). Puriﬁed wild type and N-linked glycan mutant NS1,
used at equivalent concentrations, demonstrated no differences in
NS1 binding to the cell surface (Fig. 3I). Similar results were obtained
if cells were incubated with unpuriﬁed bulk concentrated super-
natants containing equivalent concentrations of wild type andmutant
NS1 (Fig. 3J). Cell binding of wild type, N130Q, N207Q and N130Q/
N207Q required surface sulfated GAGs as treatment with 20 mM
sodium chlorate abolished binding completely (Fig. 3K). Overall, these
data suggest that N-linked glycosylation of NS1 does not directly
inﬂuence GAG interactions on the cell membrane.
Stability of secreted DENV NS1 depends on N-linked glycans
Addition of N-linked glycans to viral proteins can inﬂuence folding,
stability and solubility (Doms et al., 1993; Malvoisin and Wild, 1994;
Ng et al., 1990; Rademacher et al., 1988). Because less (10 to 25-fold,respectively) N207Q and N130Q/N207Q NS1 are present in the
supernatant of SINV-DENV-2-NS1 infected cells compared to the wild
type or N130Q mutant (Fig. 2C), we tested whether the N-linked
glycosylation at N207 affected NS1 stability. To begin, we ﬁrst
conﬁrmed that the appropriate type of N-linked glycan was present
on NS1 in the context of the SINV expression system. Supernatants
from SINV-DENV-2-NS1 infected cells containing N207Q and N130Q/
N207Q NS1 were adjusted to the same concentration (2.0 μg/ml) as
wild type or N130Q NS1. All NS1 were digested with endoglycosidase
H (Endo H), which removes high-mannose-content sugars (Tarentino
and Maley, 1974), or peptide N-glycosidase F (PNGase F), which
cleaves high mannose, hybrid, and complex oligosaccharides from N-
linked glycoproteins (Maley et al., 1989; Tarentino et al., 1985).
Predicted molecular sizes of undigested wild type, N130Q, N207Q and
N130Q/N207Q NS1 are 48, 39, 43, and 37 kDa, respectively (Figs. 4A
and B, lanes 1, 3, 5 and 7). After treatment with Endo H, only the wild
type and N130Q NS1, but not N207Q nor N130Q/N207Q NS1, were
digested to 45 and 37 kDa, respectively (Fig. 4A, lanes 2 and 4). In
comparison, all NS1 except N130Q/N207Q showed a shift in migration
to 37 kDa after treatment with PNGase F (Fig. 4B, lanes 2, 4, 6 and 8).
These results conﬁrm that NS1 synthesized in cells using the SINV
Fig. 4. The N-linked glycan at N207 inﬂuences the rate of accumulation and stability of secreted DENV NS1. Secreted NS1 from SINV-DENV2-NS1 infected BHK cells (2 μg/ml) was
treated with Endo H (A) or PNGase F (B) for 3 h at 37 °C. Western blot analysis of enzyme digested NS1 was assessed by 4–12% SDS-PAGE under reducing conditions using 1F11 anti-
DENV2-NS1MAb. (C and D) BHK21 cells infected at anMOI of onewere harvested at 14 h and thenwere radiolabeled with [35S] and chased at different time points. Supernatants (C)
and lysates (D) were collected, pre-cleared with isotype control Sepharose, and immunoprecipitated with 1F11 anti-DENV-2 NS1MAb and protein A-Sepharose. (E–H)Western blot
analysis of secreted NS1. Supernatants containing 2 μg/ml of wild type (E), N130Q (F), N207Q (G), and N130Q/N207Q (H) NS1 were incubated at 37 °C prior to analysis by 12% SDS-
PAGE under reducing conditions followed by Western blotting with 1F11 anti-DENV2 NS1 MAb. Results are representative of two or three independent experiments. I. Using
quantitative densitometry, the intensity of wild type, N130Q, N207Q, and N130Q/N207Q NS1 at each time point was compared to the level of NS1 (100%) at the starting time (0 h).
Error bars indicate standard error of the mean corresponding to three independent experiments.
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DENV infection (Crabtree et al., 2005; Pletnev et al., 1993): a complex-
type sugar at N130 and a high mannose sugar at N207.
Given that there was no detectable change in carbohydrate
modiﬁcations, we assessed the role of individual N-linked glycans
on the stability of secreted NS1. Pulse-chase labeling followed by
immunoprecipitation was performed, and wild type and mutant NS1
were analyzed in the cell-associated and extracellular pools. At the
start time of the chase (0 h), the intracellular expression levels of wild
type, N130Q, N207Q, and N130Q/N207Q were comparable (Fig. 4D).
Over time, as expected, the signal in the cell lysates declined as NS1
was secreted into the supernatant to varying degrees (Fig. 4C).
Intracellular NS1 showed aminimal difference in gel migration during
the chase period for each mutant, reﬂecting the addition of high
mannose glycans for each available N-linked glycosylation site. In
comparison, NS1 in the supernatant showed a pattern consistent with
conversion of the N-linked glycan at N130 to a larger complex-type
oligosaccharide (Winkler et al., 1988). Consistent with the ELISA
results (see Fig. 2C), labeled forms of wild type and N130Q NS1
accumulated to higher levels than N207Q or N130Q/N207Q. As the
NS1 levels in the lysates of cells expressing N207Q and N130Q/N207Q
were relatively similar compared to wild type and N130Q, the lower
amounts of N207Qmutants in the supernatant were not caused by theinstability of nascently generated intracellular NS1. To assess the
effect of N-linked glycans on the stability of secreted NS1, serum-free
supernatants of SINV-DENV-2-NS1 infected cells were harvested at
18 h post-infection, concentrated, adjusted to equal NS1 concentra-
tion (2 μg/ml), and incubated at 37 °C. At indicated time points, equal
amounts of each NS1 were subjected to SDS-PAGE under reducing
conditions, and immunoblotted with the 1F11 NS1-speciﬁc MAb.
Remarkably, little change in the levels of soluble wild type or N130Q
NS1 was observed during a 48 h incubation period (Figs. 4E and F). In
contrast, N207Q and N130Q/N207Q showed time-dependent degra-
dation after 12 and 18 h, respectively (Figs. 4G and H). Using
quantitative densitometry, we calculated the half-life of the wild
type and variant NS1 in solution: whereas wild type or N130Q was
quite stable (t 1/2N48 h), N207Q and N130Q/N207Q showed more
rapid degradation (t 1/2 of 17.2 and 23.4 h respectively) (Fig. 4I).
Overall, these data suggest that the high mannose N-linked glycan at
N207 affects both the rate of accumulation and the stability of se-
creted DENV NS1.
N-linked glycosylation inﬂuences stability of hexameric NS1
Given thatN-linked glycans affected the stability of NS1 in solution,
we evaluated their impact on oligomer formation. DENV andWNVNS1
259P. Somnuke et al. / Virology 413 (2011) 253–264can be isolated as dimers, hexamers, and even larger-order oligomers
in solution after chromatography (Avirutnan et al., 2010; Flamand
et al., 1999). To evaluate the effect of N-linked glycans on oligomer
formation, the peak elution fractions from an antibody (2G6)
immunoafﬁnity column of NS1 variants were subjected to size
exclusion chromatography on a Superdex 200 column with standards
ranging from 17 to 675 kDa (Fig. 5A). Wild type NS1, with (Fig. 5C) or
without (Fig. 5B) a carboxy terminal hexa-histidine tag, that was
isolated by immunoafﬁnity chromatography after alkaline (pH 11.5)Fig. 5. TheN-linked glycan at positionN130 is required for stabilization of the secreted hexame
fractions of NS1 were pooled and adjusted to 30 μg/ml. Size exclusion proﬁles of afﬁni
column. Samples included standard proteins (A), wild type NS1 without hexa-histidine tag (B
(F). (G–I) Size exclusion chromatography of NS1 lacking hexa-histidine tag in bulk supernat
infected BHK cells at 18 h post-infection were treated with 0.05 unit of thrombin for 16 h a
subjected to 4–12% SDS-PAGE under reducing conditions, followed by Western blotting wit
supernatants (1 ml) were injected onto a Superdex 200 column. Samples of eluted fractions w
blot with 1F11 anti-DENV-2 NS1 (wild type (H), N130Q (I)). Results are representative of thelution according to standard NS1 puriﬁcation protocols (Alcon et al.,
2002; Avirutnan et al., 2006; Flamand et al., 1999; Youn et al., 2010),
showed similar size exclusion proﬁles consisting of dimer (~77 kDa),
hexamer (~285 kDa) and a higher-order oligomer with a predicted
size of larger than 675 kDa. In contrast, themajor population of N130Q
was the higher-order oligomer. Although a ~49 kDa monomer pop-
ulation was present, the hexameric species was noticeably absent
(Fig. 5D). For the N207Q variant, a slightly larger, ~343 kDa
“hexameric” peak (fraction A10) compared towild type NS1 (fractionsr. (A–F) Size exclusion chromatography of immunoafﬁnity puriﬁedDENV-NS1. Thepeak
ty-puriﬁed NS1 was determined by injecting 1 ml of sample onto a Superdex 200
), wild type NS1 with hexa-histidine tag (C), N130Q (D), N207Q (E) and N130Q/N207Q
ants. Serum-free supernatants harvested from SINV-DENV-2-wild type or N130Q NS1-
t room temperature and concentrated 50-fold. A portion of thrombin-treated NS1 was
h 1F11 anti-NS1 MAb or anti-His6 antibody (G). Thrombin-treated wild type or N130Q
ere boiled prior to 4–12% SDS-PAGE under reducing condition and analyzed byWestern
ree to four independent experiments.
Fig. 6. Loss of N-linked glycan at position N130 affects NS1 binding to human
complement components. Equal amounts (5 μg/ml) of NS1 in culture supernatants
were used in complement binding ELISA. Concentration was determined by: (A) direct
coating of NS1 to microtiter plates and detection with anti-His6 tag MAb, and
(B) Western blot with 1F11 anti-DENV-2 NS1. Binding of wild type and mutant NS1 to
human complement components was assessed by ELISA (C). Microtiter plates were
coated with BSA, complement protein C4, C4b, C1s proenzyme or C1s (15 μg/ml).
Supernatants with equal concentrations (5 μg/ml) of wild type or mutant NS1 from
SINV-DENV-2-NS1-infected cells were added and bound NS1 was detected.
(D) Hexameric NS1 interacts most efﬁciently with complement components.
Immunoafﬁnity puriﬁed wild type NS1 hexamer and dimer isolated from a Superdex
200 column at equimolar concentration (40 nM) were added to BSA or complement
components and bound NS1 was detected with anti-His6 tag MAb. Error bars indicate
standard error of the mean corresponding to 3 or 4 independent experiments. Asterisks
indicate binding that is statistically different compared to (C) wild type DENV2 NS1 or
(D) hexameric NS1 (n.s., not signiﬁcant; *, Pb0.05).
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monomer and higher-order oligomer (Fig. 5E). The size exclusion
proﬁle of N130Q/N207Q NS1 followed the pattern of N130Q, with NS1
species found primarily as monomer and higher-order oligomer
(Fig. 5F).
Elution at high pH (11.5) from the immunoafﬁnity column could
differentially affect protein stability and oligomer formation of the
variant NS1. To conﬁrm that a change in oligomer formation was not
an artifact of the alkaline elution, we independently puriﬁed hexa-
histidine tagged versions of wild type and N130Q NS1 by nickel-
afﬁnity column under neutral pH (7.3) elution conditions. Based on
immunoblot analysis of SDS detergent-treated samples, two species of
wild type (Supplementary Fig. 1A) and N130Q (Supplementary
Fig. 1C) NS1 were detected by electrophoretic analysis, a monomer
and dimer, although the ratios were distinct with less of the
monomeric form of the mutant NS1. The peak fractions (A2) from
the nickel-afﬁnity column of wild type and N130Q NS1 were also
subjected to size exclusion chromatography. Similar to the results
seen after immunoafﬁnity chromatography with high pH elution (see
Figs. 5C and D), wild type NS1 eluted predominantly as a hexamer
(Supplementary Fig. 1B) whereas N130Q NS1 eluted largely as a
higher-order oligomer (Supplementary Fig. 1D).
To validate these ﬁndings, we analyzed the oligomeric state of NS1
directly in the supernatants without afﬁnity puriﬁcation. To ensure
that the carboxy terminal hexa-histidine tag did not inﬂuence the
oligomeric stage of NS1, serum-free supernatants from SINV-DENV-2-
wild type or N130Q NS1 infected cells were treated with 0.05 unit of
thrombin prior to size exclusion chromatography. Cleavage of the
hexa-histidine tag from the carboxy terminus of NS1was conﬁrmed by
Western blottingwith 1F11 or anti-His6 antibody (Fig. 5G). Thrombin-
treated samples showed a slight reduction in molecular weight
compared to untreated samples as detected by anti-NS1 MAb 1F11.
Importantly, only untreated samples were reactive with anti-His6
antibody. These results indicated that thrombin efﬁciently removed
the hexa-histidine tag from wild type and N130Q NS1. Subsequently,
the thrombin treated supernatants were injected onto a Superdex 200
size exclusion column, followed by reducing SDS-PAGE and Western
blot with 1F11 anti-NS1MAb. Supernatants containing both wild type
NS1 and N130Q NS1 showed mixed populations including dimer,
hexamer, and higher-order oligomers (Figs. 5H and I). Analogous to
the sizing proﬁle of afﬁnity-puriﬁed NS1, themajor population of wild
type NS1 in supernatants was hexamer (fractions A10 and A11). In
contrast to the size exclusion proﬁles of afﬁnity-puriﬁed NS1 in which
the hexamer peak was absent (Fig. 5D and Supplementary Fig. 1D),
bulk supernatant containing N130Q also contained hexameric NS1
(Fig. 5I, fraction A11). However, the primary elution peaks of N130Q
(fractions A8 and A9) corresponded to forms of NS1 that were larger
than hexamer (Fig. 5I). Taken together, these data suggest that N130
inﬂuences the oligomeric assembly of secreted NS1 by affecting the
efﬁciency of the generation and/or stabilization of the secreted
hexamer.
Loss of N-linked glycan at N130 affects NS1 binding to human
complement components
A previous study showed that DENV NS1 binds C4 and C1s to
antagonize complement activation (Avirutnan et al., 2010). We
therefore investigated the impact of N-linked glycans on these
interactions. Complement components were coated on an ELISA
plate, and serum-free supernatants from BHK21 cells infected with
SINV-DENV-2-NS1 containing wild type and variant NS1 (N130Q or
N207Q) at a concentration of 5 μg/ml were added to each well. Bound
NS1 was detected by anti-His6 antibody. Importantly, equivalent
amounts ofwild type andmutant NS1were applied as judged by ELISA
or immunoblot (Figs. 6A and B). While both wild type and N207Q NS1
interacted efﬁciently with human C4, C4b, C1s proenzyme, and C1s,N130Q NS1 showed reduced binding (Fig. 6C) (Pb0.05), suggesting
that the complex-type glycan at N130 is required for efﬁcient NS1
interaction with complement. Because N130 modulates secreted NS1
hexamer generation and/or stability, it is also possible that the low
level of NS1 hexamer in N130Q supernatant is responsible for the
reduction in complement interaction. To evaluate whether the
oligomeric state of DENV NS1 inﬂuences the binding to complement
components, immunoafﬁnity puriﬁed wild type NS1 was subjected to
size exclusion chromatography to separate hexamer and dimer (see
Fig. 5C). At equimolar amounts, hexameric NS1 showed enhanced
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These data suggest that the altered oligomeric state and decreased
amount of hexamer associatedwith secretion of N130QNS1 explain, in
part the reduced binding to complement proteins.
Discussion
Although the signiﬁcance ofN-linked glycans on Flavivirus NS1 has
been evaluated by several groups over the past two decades, an
impediment to its study has been the reduced growth of infectious
viruses containing mutations that abolish carbohydrate addition
(Crabtree et al., 2005; Muylaert et al., 1996; Pryor et al., 1998; Tajima
et al., 2008). To circumvent this, we expressed wild type and N-linked
glycan mutated forms of NS1 as a transgene using a double
subgenomic SINV. Rather than generate N→A mutations that abolish
the N-linked glycan site (Crabtree et al., 2005; Muylaert et al., 1996;
Pryor et al., 1998; Pryor and Wright, 1994; Tajima et al., 2008), we
engineered, like several other groups, the more minimal N→Q to
retain polarity and size of the amino acid side chain (Ito et al., 2007a;
Ito et al., 2007b; Kayser et al., 2011; Zhou and Tsai, 2009). Using the
double subgenomic expression system, we showed as expected, (a)
wild type or mutant NS1 had no differential effect on SINV replication
and (b) the total intracellular levels of wild type andmutant NS1were
comparably produced. With this as a starting point, we deﬁned how a
loss of individual N-linked glycans modulated surface expression,
secretion, stability, oligomer formation, and binding phenotypes.
Our experiments suggest that a loss of N-linked glycans at N207
but not N130 of DENV NS1 resulted in reduced secretion. Although
analysis of N-linked glycans on secretion of Flavivirus NS1 has been
studied previously, the results have varied (Flamand et al., 1999;
Muylaert et al., 1996; Pryor and Wright, 1994). Consistent with our
data, transient transfection of DENV NS1 encoded by an expression
plasmid in COS-7 cells also showed that mutation of N207 diminished
secretion (Pryor and Wright, 1994). In contrast, NS1 secretion from
SW13 human adrenal carcinoma cells was impaired in YFV lacking N-
linked glycans at N130 (Muylaert et al., 1996). Moreover, treatment of
DENV-1 infected Vero cells with N-linked glycosylation inhibitors (i.e.
swainsonine and deoxymannojirimicin) that blocked conversion to
complex-type sugars at N130 also decreased NS1 secretion (Flamand
et al., 1999). The apparent discrepancy in the latter two studies with
infectious virus may be explained by the confounding effects on the
replication: mutation of YFV N130 and treatment of DENV-infected
cells with N-linked glycosylation inhibitors impaired viral infectivity,
which indirectly affects the accumulation of NS1 in the supernatant.
Additionally, for YFV, both ﬁrst and second glycosylation sites, in
contrast to DENV, are processed to complex-type sugars (Despres
et al., 1991; Post et al., 1991).
Based on its reduced accumulation in the supernatant, we
hypothesized that the N-linked glycan at residue N207 might regulate
NS1 transport through the secretory pathway or affect protein stability.
Indeed, a previous study suggested that a loss of the N-linked glycan at
N207 decreased intracellular levels of DENV-2 NS1 because of its
apparent effects on dimer stability (Pryor andWright, 1994). However,
our pulse-chase experiments showed remarkably similar levels of
intracellular NS1. Consistentwith this,ﬂow cytometric analysis of SINV-
DENV-2 NS1 infected cells also showed equivalent total levels of wild
type and variant NS1. These results aremore concurrent with a study in
which mutation of N207 in the context of DENV-2 infection did not
affect the intracellular levels of dimeric NS1, as judged by gel
electrophoretic analysis (Pryor et al., 1998). In comparison, pulse-
chase analysis of supernatants at early time points revealed that NS1
containingmutations at N207 had a defect in secretion, which could not
be accounted for by the change in the stability. This could be due to
problems in folding of N207Q NS1, since N-linked glycans facilitate
interactions with the molecular chaperones (e.g., calnexin or calreticu-
lin) in the endoplasmic reticulum (Trombetta and Helenius, 1998). Insupport of this hypothesis, we observed conformation-dependent
binding of anti-NS1 MAbs (9NS1) and polyclonal antibodies to
intracellular or cell surface NS1 in variants containing N207Q. Thus,
the N-linked glycan at N207 likely affects secretion and extracellular
NS1 accumulation, in part because of its impact on folding.
NS1 on the cell surface in Flavivirus infection can arise from two
independent sources: (a) soluble NS1 binds back to the plasma
membrane through interactions with sulfated GAGs (Avirutnan et al.,
2007); and (b) NS1 is directly transported to and expressed on the
plasma membrane, although it lacks a transmembrane domain or
canonical targetingmotif (Winkler et al., 1988, 1989). Our experiments
suggested that the N-linked glycan at position N207 but not N130 was
required for efﬁcient cell surface attachment of NS1. To distinguish
between the “binding back” and “direct transport” mechanisms, we
assessed surface levels of wild type andN-linked variants of NS1 in cells
treated with sodium chlorate, which inhibits sulfated GAG production
and NS1 binding back to cell surface (Avirutnan et al., 2007). When
GAGsweredepleted from thecell surface, thedifference in surface levels
of NS1 between the wild type, N130Q, N207Q, and N130Q/N207Q
disappeared, suggesting that differential N-linked glycosylation did not
affect direct transport of NS1 to the cell surface. Consistent with this, a
mutant WNV NS1 lacking all three conserved N-linked glycosylation
sites did not affect plasma membrane expression (Youn et al., 2010).
Taken together, our experiments suggest that the higher cell surface
expression levels of wild type and N130Q compared to that of N207Q
and N130Q/N207Q NS1 is due to the greater secretion, extracellular
accumulation, and binding back to the plasma membrane.
A previous study suggested that the conformation of DENV NS1
might change during the transit through the Golgi system such that
complex-type N-linked glycans induced or stabilized a mature form of
NS1 hexamer (Flamand et al., 1999). This hypothesis is consistent
with our results showing the lack of complex-type oligosaccharides at
N130 resulted in a loss of hexameric NS1 and an increase in the
higher-order oligomers after puriﬁcation. This effect, however, was
not just associated with highly puriﬁed forms of NS1, as size exclusion
chromatography of bulk supernatant from SINV-DENV-2 N130Q NS1
infected cells also showed a relative decrease in the hexamer and
increase in higher-order oligomer. The phenotype though was less
apparent, possibly because secreted cellular proteins may stabilize
hexamer formation even for NS1 lacking the N130 N-linked glycan.
Interaction of Flavivirus NS1 with the complement components C4,
C1s, and factor H protects virus and infected cells from immune
recognition and neutralization (Avirutnan et al., 2010; Chung et al.,
2006a). NS1 proteins lacking the N-linked glycan at N130 showed
reduced binding to C1s and C4 compared to wild type and N207Q NS1.
This could be due to the skewing of oligomeric forms of N130Q as
hexameric NS1 bound more efﬁciently to complement components
compared to otherNS1 species. Alternatively,N-linkedglycan atposition
N130 may directly participate in the interaction between NS1 and
complement components. Interestingly, despite its defect in relative
secretion, the N207Q mutant still efﬁciently bound complement
components. We speculate that the DENV-2 variants having an N207Q
mutation, which show no apparent growth defect in cell culture but are
attenuated in mice (Pryor et al., 1998), are less virulent in part, because
the low levels of secreted NS1 generated are not sufﬁcient to protect the
virus from complement attack. In summary, the twoN-linked glycans on
DENV-2 NS1 differentially regulate surface expression, secretion,
stability, and complement binding. Our study provides new insight as
tohowN-linkedglycosylation ofNS1 is linked to its biological properties.
Materials and methods
Cell culture
BHK21 (clone 15) cells were grown in Dulbecco's modiﬁed Eagle's
medium (DMEM, Sigma) supplemented with 10% fetal bovine serum
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10 mM HEPES, pH 7.3, and 10 mM nonessential amino acids (Cellgro)
in a 5% humidiﬁed CO2 incubator at 37 °C.
Generation and puriﬁcation of wild type and mutant DENV NS1
Recombinant wild-type or N130Q, N207Q, and N130Q/N207Q
mutants of DENV-2 NS1 were expressed as a transgene using a double
subgenomic Sindbis virus (SINV) expression system with the SINV 39
E2H55K70 infectious cDNA clone (39HK; gift of W. Klimstra,
Pittsburgh, PA) (Ryman et al., 2007). Brieﬂy, the DENV-2 NS1 gene
of strain 16681, including a 24-amino acid leader sequence from the
carboxy terminus of the E gene, was ampliﬁed from infected Vero cells
by RT-PCR using the following oligonucleotide primers (NS1 sequence
underlined): forward, 5′ GCGGCCGCACCATGGTCTCACTGTCTGTGA-
CACTAG 3′; reverse, 5′ TCAAGCTGT GACCAAGGAGTTGAC 3′. The
product was subcloned into the 39HK backbone after digestion with
NotI and PmeI restriction enzymes. SINV 39HK-DENV-2 NS1 was also
introduced with a hexa-histidine tag at the carboxy-terminus by PCR
using the following oligonucleotide primers: forward, 5′
GCGGCCGCACCATGGTCTCACTGTCTGTGACACTAG 3′; reverse, 5′
TCAATG ATGATGATGATGATGTGATCCACGAGGAACTAGAGCTGTGAC-
CAAGGAGTTGAC 3′. Site-speciﬁc mutations were introduced into
the wild type DENV-2 NS1 after subcloning into the AT vector
(Novagen) using QuickChange II Site-Directed Mutagenesis Kit
(Stratagene). The mutations included N130→Q, N207→Q, and
N130→Q/N207→Q double mutant using the following oligonucle-
otide primers: N130Q forward 5′ GCTCTCTACAGAGTCTCAT CAACA-
GACCTTTCTCATTGATGG 3′; N130Q reverse 5′ CCATCAATGAGAA
AGGTCTGTTGATGAGACTCTGTAGAGAGC 3′; N207Q forward 5′ GGA-
TAGAAA GTGCACTCCAAGACACATGGAAGATAGAGAAAGC 3′; N207Q
reverse 5′ GCTTTC TCTATCTTCCATGTGTCTTGGAGTGCACTTTCTATCC
3′. After NotI restriction enzyme digestion, wide type and mutant NS1
were cloned into 39HK double subgenomic SINV cDNA. The cloning
and mutagenesis were veriﬁed by sequencing on both strands.
Plasmids were subsequently linearized with XhoI and transcribed in
vitro using SP6 DNA-dependent RNA polymerase (mMESSAGE
mMACHINE kit, Ambion, Austin, TX). RNA was electroporated into
BHK21 cells with 3 consecutive electrical pulses of 850 V at 25 μF and
∞ Ω using Gene Pulser Xcell electroporator (BioRad). Recombinant
SINV were collected at 24 h post-infection and titrated by plaque
assay on BHK21 cells.
To generate puriﬁed NS1, SINV encoding wild type, N130Q, N207Q
or N130Q/N207Q NS1were used to infect BHK21 cells at a multiplicity
of infection (MOI) of one in serum-free DMEM. Supernatant was
harvested at 24 h after infection and infectious SINV was inactivated
after addition of 0.05% NP-40. Wild type and mutant NS1 were
puriﬁed by 2G6 anti-DENV-2 NS1 MAb afﬁnity chromatography
(Avirutnan et al., 2006) after elution with diethylamine (Sigma) pH
11.5. In some experiments, NS1 containing a carboxy-terminal hexa-
histidine tag was puriﬁed by nickel afﬁnity chromatography (GE
Healthcare) using an imidazole (EMD Chemicals) elution gradient at
pH 7.3. The peak fractions containing NS1 were subjected to Superdex
200 size exclusion chromatography (GE Healthcare) as described
previously (Avirutnan et al., 2010).
Analysis of surface and total SINV E2 and DENV-2 NS1 expression
BHK21 cells were infected with SINV-DENV-2 NS1 at an MOI of one
and harvested at 18 h post-infection. For total antigen detection,
infected cells were ﬁxed with 4% paraformaldehyde, permeabilized
with 0.1% (w/v) saponin (Sigma), and incubated with either 1:400
mouse hyper-immune serum against SINV E2 (ATCC) or 1F11
(recognizing a linear epitope) anti-DENV2 NS1 MAb (Puttikhunt et al.,
2003) followed by 4 μg/ml Alexa Fluor-647 goat anti-mouse IgG
(Invitrogen). For analysis of surface antigens, unﬁxed cells were stainedwith antibodies as described above and propidium iodide (0.5 μg/ml,
Molecular Probes) was added to exclude dead cells. Alternatively,
infected cells were incubatedwith conformation-dependent 9NS1MAb
(Chung et al., 2006b) or polyclonal anti-DENV-2 NS1. In some
experiments, cells were infected with SINV-DENV-2 NS1 viruses for
6 h,washed5 timeswithPBS, andSO4 free JoklikModiﬁcationMinimum
Essential Medium Eagle (Sigma) supplemented with 20 mM sodium
chlorate (Sigma) was added to prevent generation of sulfated GAGs
(Baeuerle and Huttner, 1986). Levels of surface and total NS1 were
assessed by ﬂow cytometry (FACSCalibur, BD Biosciences). Data were
processed with CellQuest Pro software (Becton Dickinson).
DENV-2 NS1 ELISA
Maxi-Sorp microtiter plates (Nunc) were coated with 5 μg/ml of
2E11 anti-DENV2 NS1 MAb (Puttikhunt et al., 2003) at 4 °C overnight.
Non-speciﬁc binding sites were blocked with 2% bovine serum
albumin (BSA, Sigma) in PBS for 2 h at room temperature. After ﬁve
washes with 0.05% Tween-20 in PBS (PBST), 50 μl of cell supernatants
from SINV-DENV-2-NS1 infected cells or puriﬁed NS1 (diluted in PBS
containing 0.1% BSA) was added to each well and incubated for 1 h at
room temperature. The plates were washed ﬁve times with PBST
followed by sequential 1 h incubations at room temperature with
50 μl of 2 μg/ml mouse anti-His6 antibody (Quidel), 1 μg/ml biotiny-
lated goat anti-mouse IgG (Sigma) and 1 μg/ml HRP-conjugated
streptavidin (Vector Laboratories). After six ﬁnal PBS washes, signal
was developed by adding 50 μl of TMB substrate (DAKO) and 25 μl of
2 N H2SO4 stop solution to each well. The optical density (O.D.) at
450 nm was determined by a 96-well plate reader (Genio Pro; Tecan
Instruments).
NS1 binding to BHK21 cells
BHK21 cells were incubated with supernatants containing 2 μg/ml
NS1 as determined by NS1 capture ELISA. After a 1 h incubation on ice,
the cells were incubated with 2G6 anti-DENV2 NS1 MAb (Puttikhunt
et al., 2003) followed by 4 μg/ml Alexa Fluor-647 goat anti-mouse IgG
and 0.5 μg/ml propidium iodide to exclude dead cells. Levels of NS1 on
the cell surface were determined by ﬂow cytometry. In some
experiments, puriﬁed wild type or mutant NS1 (10 μg/ml) were
used instead of supernatants. To reduce cell-associated sulfated GAGs
(Baeuerle and Huttner, 1986), BHK21 cells were washed 5 times with
PBS and incubated overnight in SO4 free DMEM supplemented with
20 mM sodium chlorate prior to NS1 binding.
SDS-PAGE and Western blot analysis
Puriﬁed NS1 or supernatant from SINV-DENV-2-NS1 virus-
infected BHK21 cells was collected and boiled at 98 °C for 10 min
prior to 4–12% SDS-PAGE (NuPAGE, Invitrogen) under non-reducing
or reducing conditions. Western blots were performed using 1F11
anti-DENV-2 NS1 MAb followed by incubation with 1:5000 HRP-
conjugated goat anti-mouse IgG (GE Healthcare). Development was
with West Pico Enhanced Chemiluminescence (Thermo Scientiﬁc).
Silver staining was performed using a ProteoSilver™ Silver Stain Kit
(Sigma).
DENV-2 NS1 deglycosylation
Supernatants from SINV-DENV-2-NS1 infected BHK21 cells were
digested for 3 h with endoglycosidase H (EndoH) or peptide N
glycosidase F (PNGaseF) (NEB) according to the manufacturer's
protocols. Reactants were then subjected to 4–12% SDS-PAGE under
reducing conditions followed byWestern blot with 1F11 anti-DENV-2
NS1 MAb.
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Pulse-chase experiments were performed after infecting BHK21
monolayers (6×105 cells/well in a 6-well plate) with SINV-DENV-2-
NS1 viruses at an MOI of one for 12 h. Cells were starved by replacing
culture media with methionine- and cysteine-free DMEM (Invitro-
gen) for 15 min, incubated with 50 μCi [35S]cysteine–methionine for
20 min, washed with PBS, and cultured for indicated times with
complete DMEM supplemented with 10% FBS. Supernatants and cell
lysates were collected at 0, 2, 4, and 8 h after labeling, pre-cleared
with anti-Flavivirus E (4G2) isotype control MAb-Sepharose and
immunoprecipitated at 4 °C overnight with anti-DENV NS1 speciﬁc
(1F11) MAb and protein G-Sepharose (Invitrogen). Immunoprecipi-
tates were washed three times with RIPA buffer (10 mM Tris pH 7.4,
0.1% SDS, 1% sodium deoxycholate, 1% NP-40, 0.15 MNaCl) and bound
proteins were eluted in SDS reducing sample buffer, heated at 98 °C
for 3 min, and subjected to 12% SDS-PAGE under reducing conditions.
Gels were dried, soaked for 30 min in Amplify (GE Healthcare), and
exposed to an intensifying X-ray ﬁlm (Kodak).
Thrombin cleavage of hexa-histidine tag
Supernatants from SINV-DENV2-NS1 infected BHK21 cells were
collected at 18 h post-infection and treated with 0.05 unit of thrombin
(Enzyme Research) for 16 h at room temperature. Cleavage of the
hexa-histidine tag was conﬁrmed by Western blot analysis with anti-
NS1 MAb 1F11 and anti-His6 antibodies.
Complement protein ELISA
Maxi-Sorpmicrotiter plates were incubatedwith 15 μg/ml puriﬁed
C4, C4b, C1s proenzyme or C1s (all from Complement Technologies)
at 4 °C overnight. Plates were washed 5 times with PBS and non-
speciﬁc binding sites were blocked with 2% heat inactivated BSA for
2 h at 37 °C. After 5 washes with PBS, SINV-DENV-2-NS1 infected BHK
supernatants (containing 5 μg/ml of NS1 as determined by capture
ELISA) were added to the wells and incubated for 2 h at room
temperature. Plates were washed 5 times with PBST followed by
sequential 1 h incubations at room temperature with 2 μg/ml anti-
His6 MAb, 1 μg/ml biotinylated goat anti-mouse IgG, and 2 μg/ml HRP-
conjugated streptavidin. Plates were next washed 6 times with PBS,
and then the O.D. at 450 nm was evaluated as described above. In
some experiments, wild type NS1 fractions were injected onto a
Superdex 200 column to separate the NS1 hexamer and dimer
populations. Binding of these NS1 species to complement proteins
was performed by ELISA as outlined above.
Statistical analysis
Datasets were analyzed by a two-tailed, unpaired t test. Statistical
signiﬁcance was achieved when P values were b0.05. Results from the
plaque formation assay, quantitative NS1 ELISA and complement-NS1
binding ELISA were analyzed with Prism software (GraphPad
Software, Inc.). Simple linear regression analysis of the ELISA data
was analyzed using StatView software (SAS Institute, Inc.).
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.02.022.
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